Marcus Ladds

Marcus Ladds has 15 years of experience in mass spectrometry across multiple disciplines including DMPK and proteomics. He joined AstraZeneca in 2022 and is responsible for the design of assays utilising mass spectrometry to drive drug discovery efforts within the Assays, Profiling and Cell Sciences Department for both profiling and MoA studies. Marcus obtained his BSc and MSc at the University of Auckland (New Zealand) in Biomedical Science with a project looking at metabolism of prodrugs in vivo. He then went on to study his PhD at the Karolinska Institute (Sweden) under Prof. Sonia Lain and Prof. Sir David Lane where he co-led a project looking for reactivators of wild-type p53 function in a high throughput phenotypic screen and subsequent target deconvolution and optimisation of medicinal chemistry. He has been involved in the publication of 14 peer-reviewed articles and is an active organiser of the Cambridge Proteomics and Mass Spectrometry meetings in the UK.